66648-29-1

Basic information

• Product Name: Propanoic acid, 2-[[(4-methylphenyl)sulfonyl]oxy]-, methyl ester
• CAS NO: 66648-29-1
• Molecular Formula: C11H14O5S
• Molecular Weight: 258.295
• Mol File: 66648-29-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 2-[[(4-methylphenyl)sulfonyl]oxy]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 2-[[(4-methylphenyl)sulfonyl]oxy]-, methyl ester(66648-29-1)
• EPA Substance Registry System: Propanoic acid, 2-[[(4-methylphenyl)sulfonyl]oxy]-, methyl ester(66648-29-1)

Safety Data

• Hazardous Substances Data: 66648-29-1(Hazardous Substances Data)

Upstream product

• 547-64-8 methyl lactate 
• 98-59-9 p-toluenesulfonyl chloride 
• 104-15-4 toluene-4-sulfonic acid 
• 67-56-1 methanol 
• 27126-76-7 [hydroxy(tosyloxy)iodo]benzene 
• 123-62-6 propionic acid anhydride 

Downstream Products

• 71283-66-4 (-)-(S)-Methyl 2-<(p-tolylsulfonyl)oxy>propionate 
• 109579-04-6 methyl (2R)-2-{[(4-methylphenyl)sulfonyl]oxy}propanoate 
• 95262-84-3 2-(4-chlorophenoxy)propanoic acid methyl ester 
• 79005-47-3 2-(4-nitrophenoxy)-propionic acid methyl ester 
• 51338-27-3 diclofop-methyl 
• 58594-77-7 D-(+)-2-[4-(4-trifluoromethylphenoxy)-phenoxy]-propionic acid methyl ester 

Relevant articles and documents

Cyclohexane-1,3-diketone compound as well as synthesis method and application thereof

The invention provides a cyclohexane-1,3-diketone compound of which the structural formula is shown in the specification, wherein the group R1 in the structural formula I is -CH3, -CH2CH3, -(CH2)2CH3,-CH(CH3)2, -(CH2)3CH3, -CH(CH3)C2H5, -CH2CH(CH3)2 or -C

New CRTh2 antagonists.

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

NEW CRTh2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.